Other studies have shown that inhibition of SUMOylation can attenuate cystic fibrosis via CFTR (Borgo et al., 2024; Peters et al., 2021), confirming that CFTR is a vital therapeutic target against cystic fibrosis. The gene discussed is CFTR; the disease is cystic fibrosis.